Platinum-Based Chemo for Bladder Cancer Linked With Increased Thromboembolism Risk

Share this content:
Patients receiving platinum-based chemotherapy were at higher risk of developing thromboembolism.
Patients receiving platinum-based chemotherapy were at higher risk of developing thromboembolism.

Patients receiving platinum-based chemotherapy were at higher risk of developing thromboembolism, particularly within the first year after diagnosis, a new study published online ahead of print in the Journal of Urology has shown.1

Because platinum-based chemotherapy is associated with vascular toxicity when used for the treatment of bladder cancer, a team of researchers led by Amit Gupta, MD, MPH, assistant professor in the Department of Urology at the University of Iowa in Iowa City, sought to evaluate the short-term and intermediate-term vascular toxicity of platinum chemotherapy in older patients with bladder cancer.

Researchers analyzed data from 5,057 patients age 66 to 94 diagnosed with stage 2-3 bladder cancer between 1998 and 2007 included in the SEER database. Of those, 21.3% received platinum-based chemotherapy.

Results showed that during the first year after diagnosis, patients who received platinum-based chemotherapy had a higher risk of thromboembolic events compared with those who did not receive chemotherapy (HR = 1.43; 95% CI: 1.17-1.75). Researchers found that the risk of thromboembolism is similar for both carboplatin and cisplatin.

RELATED: Circulating Tumor Cell Assays May Play Role in Bladder Cancer Management

During the 2 to 5 years after diagnosis, the study demonstrated no significant association between platinum-based chemotherapy and the risk of thromboembolic events.

Of note, platinum chemotherapy did not increase the risk of non-thromboembolic vascular events during either time period.

References

  1. Gupta A, Long JB, Chen J, et al. Risk of vascular toxicity with platinum-based chemotherapy in elderly patients with bladder cancer [published online ahead of print September 1, 2015]. J Uro. doi: 10.1016/j.uro.2015.08.088.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters